#EXAS

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect ® molecular residual disease test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group, demonstrated that the...

3 months ago

#EXAS Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0

3 months ago

Just In: ( NASDAQ: #EXAS ) Here's Why Grail Soared, Again, in November

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #EXAS ) This Top Dividend King Just Became an Even Better Buy

1 0 0 0

Investigation Alert: Happy Thanksgiving and M&A Updates on Major Companies This Thanksgiving, Monteverde & Associates is examining mergers involving EXAS, SEE, CDTX, and MRSN. Are shareholders getting a fair deal?

3 months ago

NEWS: ( NASDAQ: #EXAS ) EXAS Price Target Alert: $105.00. Issued by Stifel Nicolaus

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Investigation Alert: Happy Thanksgiving and M&A Updates on Major Companies #United_States #New_York #Monteverde_Law #SEE #EXAS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Halper Sadeh LLC Urges Shareholders Of GDOT, BLFY, EXAS To Discuss Their Rights Halper Sadeh LLC is calling on shareholders of GDOT, BLFY, and EXAS to reach out regarding potential rights violations and corporate transactions.

Halper Sadeh LLC Urges Shareholders Of GDOT, BLFY, EXAS To Discuss Their Rights #USA #New_York #Halper_Sadeh #GDOT #EXAS

0 0 0 0

3 months ago

JUST IN: ( NASDAQ: #EXAS ) Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

1 0 0 0

3 months ago

News; ( NASDAQ: #EXAS ) EXAS Price Target Alert: $105.00. Issued by Piper Sandler

0 0 0 0

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium Exact Sciences (Nasdaq: EXAS) will present 10 abstracts at the 2025 San Antonio Breast Cancer Symposium, Dec 9-12, highlighting clinical validation and real‑world data across its Precision Oncology portfolio.Key items include the first clinical validation of the Oncodetect test in triple‑negative breast cancer with highly sensitive MRD detection, a large ongoing NSABP B‑64 trial enrolling >1,800 patients with readouts starting in 2027, and multiple Oncotype DX studies showing improved outcomes, guideline‑concordant use across racial and ethnic groups, and an estimated >€60M chemotherapy cost savings in Ireland.

3 months ago

#EXAS Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0

3 months ago

JUST IN: ( NASDAQ: #EXAS ) EXAS Price Target Alert: $105.00. Issued by Jefferies

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #EXAS ) Hold Recommendation Issued On EXAS By Jefferies

0 0 0 0

3 months ago

Just In: ( NASDAQ: #EXAS ) EXAS Price Target Alert: $105.00. Issued by Craig-Hallum

0 0 0 0

3 months ago

BREAKING NEWS: ( NASDAQ: #EXAS ) Hold Recommendation Issued On EXAS By Craig-Hallum

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #EXAS ) Is it too late to buy Exact Sciences stock after Abbott's $21B deal?

0 0 0 0

@stockmaster70.bsky.social

3 months ago

Just In: ( NASDAQ: #EXAS ) EXAS Price Target Alert: $105.00. Issued by Robert W. Baird

0 0 0 0

Stock Master

3 months ago

📢 Stocks Trending NOW: #WMT #AVGO #EXAS #PANW #CRWV #MNDR #XYZ #AUID #BBWI #PACS

0 0 0 0

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to...

3 months ago

#ABT #EXAS Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

www.stocktitan.net/news/ABT/abbott-to-acqui...

0 0 0 0

4 months ago

#EXAS Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

4 months ago

Just In: ( NASDAQ: #EXAS ) 2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

0 0 0 0

Nasdaq

4 months ago

#EXAS #ROKU #414035e0-88ec-4ebb-ae91-d26a8d263121 #investing

Origin | Interest | Match

1 0 0 0

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test Exact Sciences (NASDAQ: EXAS) announced pivotal ALTUS study results showing its Oncoguard Liver blood test outperformed ultrasound for hepatocellular carcinoma (HCC) surveillance in a prospective U.S. trial of >3,000 participants. The test met the primary endpoint, detecting early-stage HCC by Milan criteria 67% vs 22% for ultrasound, with very early-stage sensitivity 64% vs 9% and early-stage sensitivity 77% vs 36%. Oncoguard Liver specificity was 82%. Results will be presented as late-breaking data at AASLD The Liver Meeting on November 11, 2025 and are planned for peer-reviewed publication. The assay combines DNA methylation and protein markers and was developed with Mayo Clinic.

4 months ago

#EXAS Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0

Exact Sciences Announces Third Quarter 2025 Results Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024.. “Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a...

4 months ago

#EXAS Exact Sciences Announces Third Quarter 2025 Results

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0

New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies Exact Sciences (NASDAQ: EXAS) announced a modeling study published in JNCI showing Cologuard Plus, a triennial next‑generation mt‑sDNA test, was the only noninvasive option classified as efficient for screening ages 45–75, delivering the most life‑years gained with the fewest colonoscopies.The study used the validated CRC‑AIM microsimulation and CISNET methodology, incorporated new clinical data, and reported Cologuard Plus sensitivity of 95% for CRC and specificity of 94% in U.S. screening‑age adults.Findings note annual FIT was near‑efficient; mt‑RNA and blood‑based tests were not efficient at recommended intervals.

5 months ago

#EXAS New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies

www.stocktitan.net/news/EXAS/new-study-in-j...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

#TTD #EXAS #PINS #d0a431aa-d8dd-48da-8369-a6d1e03f0e33 #investing

Origin | Interest | Match

0 0 0 0

Value The Markets

@valuethemarkets.bsky.social

7 months ago

Exact Sciences ($EXAS) posted $707M in Q1 revenue (+11%) and unveiled Cologuard Plus - a test that cuts false positives by 40%. Watch the technical breakout.

Read more 👉 buff.ly/6vqd2As
#EXAS #Biotech

Disclaimer: Info only. DYOR. buff.ly/ei9wKKV

0 0 1 0

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer Exact Sciences (NASDAQ:EXAS) has secured Medicare coverage for its Oncodetect™ molecular residual disease (MRD) test through CMS's MolDX program. The coverage applies to patients with stage II, III, and resectable stage IV colorectal cancer for a five-year period.The Oncodetect test can track up to 200 ctDNA variants and detect cancer recurrence up to two years earlier than imaging alone. The test's effectiveness is supported by clinical validation studies, including Beta-CORRECT and Alpha-CORRECT trials. This Medicare coverage decision impacts over three million Americans eligible for MRD testing across multiple solid tumors.

8 months ago

#EXAS Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

www.stocktitan.net/news/EXAS/exact-sciences...

0 0 0 0